Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 7, 2012 - Issue 3
Submit an article Journal homepage
155
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Ovarian stimulation protocols in assisted reproductive technology: an update

Colin M Howles Merck Serono S.A. – Geneva, Geneva, Switzerland; Merck Serono S.A. – Geneva, Geneva, Switzerland. [email protected]
,
Diego Ezcurra Merck Serono S.A. – Geneva, Geneva, Switzerland; Merck Serono S.A. – Geneva, Geneva, Switzerland
&
Roy Homburg Barzilai Medical Centre, Ashkelon, Israel and Homerton University Hospital, Hackney, London, UK; Barzilai Medical Centre, Ashkelon, Israel and Homerton University Hospital, Hackney, London, UK
Pages 319-330 | Published online: 10 Jan 2014

References

  • Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum. Reprod. 26(7), 1768–1774 (2011).
  • Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders. Fertil. Steril. 96(2), 344–348 (2011).
  • Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfers in high responders. Fertil. Steril. 96(2), 516–518 (2011).
  • Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum. Reprod. Update 14, 1–14 (2008).
  • Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum. Reprod. Update 9(3), 275–289 (2003).
  • Papanikolaou EG, Tournaye H, Verpoest W et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum. Reprod. 20(3), 636–641 (2005).
  • Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum. Reprod. Update 10(6), 453–467 (2004).
  • Zondek B. Über die hormone des hypophysenvorderlappens. Klin Wochenschrift 9, 245–248 (1930).
  • Gemzell C, Diczfalusy E, Tillinger G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J. Clin. Endocrinol. Metab. 18(12), 1333–1348 (1958).
  • Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European Phase III study. Hum. Reprod. 9(3), 424–430 (1994).
  • van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod. Biomed. Online 7(5), 547–557 (2003).
  • Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol. Endocrinol. 25(6), 372–378 (2009).
  • Saxena BB, Rathnam P. Amino acid sequence of the beta subunit of follicle-stimulating hormone from human pituitary glands. J. Biol. Chem. 251(4), 993–1005 (1976).
  • Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr. Med. Res. Opin. 19(1), 41–46 (2003).
  • Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod. Biomed. Online 10(2), 169–177 (2005).
  • Bassett R, Lispi M, Ceccarelli D et al. Analytical identification of additional impurities in urinary-derived gonadotrophins. Reprod. Biomed. Online 19(3), 300–313 (2009).
  • Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report. Gynecol. Endocrinol. 14(3), 149–152 (2000).
  • Landfeldt E, Jablonowska B, Norlander E et al. Patient preferences for characteristics differentiating ovarian stimulation treatments. Hum. Reprod. 27(3), 760–769 (2012).
  • Nardo LG, Fleming R, Howles CM et al. Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation. Reprod. Biomed. Online 23(2), 141–148 (2011).
  • Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin. Drug Metab. Toxicol. 5(10), 1323–1336 (2009).
  • Albano C, Smitz J, Camus M, Bennink HC, Van Steirteghem AC, Devroey P. Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotrophin. Hum. Reprod. 11(8), 1632–1634 (1996).
  • Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil. Steril. 58(5), 888–896 (1992).
  • Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr. Rev. 27(2), 170–207 (2006).
  • Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum. Reprod. 10(8), 1974–1981 (1995).
  • Ludwig M, Katalinic A, Banz C et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum. Reprod. 17(11), 2842–2845 (2002).
  • Devroey P, Aboulghar M, Garcia-Velasco J et al. Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum. Reprod. 24(4), 764–774 (2009).
  • Al-Inany HG, Youssef MA, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 5, CD001750 (2011).
  • Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a ‘freeze-all’ strategy: a prospective multicentric study. Fertil. Steril. 95(6), 2029–2033, 2033.e1 (2011).
  • Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 89(1), 84–91 (2008).
  • Griesinger G, Berndt H, Schultz L, Schultze-Mosgau A, Diedrich K, von Otte S. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study. Reprod. Biomed. Online 22(2), 133–139 (2011).
  • Cook AS, Webster BW, Terranova PF, Keel BA. Variation in the biologic and biochemical characteristics of human menopausal gonadotropin. Fertil. Steril. 49(4), 704–712 (1988).
  • Andersen CY, Ezcurra D. What is the clinical relevance of follicle-stimulating hormone isoforms in fertility treatment. Reprod. Biol. Insights 4, 1–10 (2011).
  • Giudice E, Crisci C, Eshkol A, Papoian R. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. Hum. Reprod. 9(12), 2291–2299 (1994).
  • Van Dorsselaer A, Carapito C, Delalande F et al. Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approach. PLoS ONE 6(3), e17815 (2011).
  • Kuwabara Y, Mine K, Katayama A, Inagawa T, Akira S, Takeshita T. Proteomic analyses of recombinant human follicle-stimulating hormone and urinary-derived gonadotropin preparations. J. Reprod. Med. 54(8), 459–466 (2009).
  • Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum. Reprod. 21(12), 3217–3227 (2006).
  • Devroey P, Pellicer A, Nyboe Andersen A, Arce JC; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer (MEGASET) Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil. Steril. 97(3), 561–571 (2012).
  • van Wely M, Kwan I, Burt AL et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst. Rev. 2, CD005354 (2011).
  • Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod. Biol. Endocrinol. 8, 112 (2010).
  • Garrido N, Bellver J, Remohí J, Simón C, Pellicer A. Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to measuring the likelihood of IVF success. Fertil. Steril. 96(1), 40–46 (2011).
  • Trew GH, Brown AP, Gillard S et al. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. Reprod. Biol. Endocrinol. 8, 137 (2010).
  • Fauser BC, Nargund G, Andersen AN et al. Mild ovarian stimulation for IVF: 10 years later. Hum. Reprod. 25(11), 2678–2684 (2010).
  • Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod. Biomed. Online 21(1), 66–76 (2010).
  • Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum. Reprod. 24(12), 3063–3072 (2009).
  • Santjohanser C. Letter to the editor ‘Long-acting-FSH (FSH-CTP) in reproductive medicine’. J. Gynakol. Endokrinol. 3, 183–183 (2009).
  • Norman RJ, Zegers-Hochschild F, Salle BS et al.; TRUST Investigators. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum. Reprod. 26(8), 2200–2208 (2011).
  • Baart EB, Martini E, Eijkemans MJ et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum. Reprod. 22(4), 980–988 (2007).
  • Verberg MF, Macklon NS, Nargund G et al. Mild ovarian stimulation for IVF. Hum. Reprod. Update 15(1), 13–29 (2009).
  • Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update 8(6), 559–577 (2002).
  • Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod. Biomed. Online 12(2), 221–233 (2006).
  • Nilsson C, Pettersson K, Millar RP, Coerver KA, Matzuk MM, Huhtaniemi IT. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. International Collaborative Research Group. Fertil. Steril. 67(6), 998–1004 (1997).
  • de Castro F, Morón FJ, Montoro L et al. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 14(5), 285–293 (2004).
  • Simoni M, Nieschlag E, Gromoll J. Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum. Reprod. Update 8(5), 413–421 (2002).
  • Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod. Biol. Endocrinol. 5, 9 (2007).
  • Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil. Steril. 82(5), 1323–1329 (2004).
  • Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil. Steril. 69(3), 505–510 (1998).
  • Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev. 30(5), 465–493 (2009).
  • Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil. Steril. 94(3), 1044–1051 (2010).
  • Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil. Steril. 90(3), 737–743 (2008).
  • Lee MM, Donahoe PK, Hasegawa T et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab. 81(2), 571–576 (1996).
  • Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum. Reprod. 18(2), 328–332 (2003).
  • Nelson SM, Yates RW, Lyall H et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 24(4), 867–875 (2009).
  • Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil. Steril. 95(2), 736–741.e1–e3 (2011).
  • Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum Müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil. Steril. 85(5), 1541–1543 (2006).
  • Nardo LG, Gelbaya TA, Wilkinson H et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil. Steril. 92(5), 1586–1593 (2009).
  • van Rooij IA, Broekmans FJ, te Velde ER et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17(12), 3065–3071 (2002).
  • Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum. Reprod. Update 17(1), 46–54 (2011).
  • Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-Müllerian hormone levels are negatively related to follicular output rate (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Hum. Reprod. 26(3), 671–677 (2011).
  • Abbotts C, Salgado-Braga C, Audibert-Gros C. A redesigned follitropin alfa pen injector for infertility: results of a market research study. Patient Prefer. Adherence 5, 315–331 (2011).
  • Weiss N. Gonadotrophin products: empowering patients to choose the product that meets their needs. Reprod. Biomed. Online 15(1), 31–37 (2007).
  • Somkuti SG, Schertz JC, Moore M, Ferrande L, Kelly E; Gonal-F Prefilled Pen in OI Study 24785 Group. Patient experience with follitropin alfa prefilled pen versus previously used injectable gonadotropins for ovulation induction in oligoanovulatory women. Curr. Med. Res. Opin. 22(10), 1981–1996 (2006).
  • Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod. Biomed. Online 24(3), 281–292 (2012).
  • Christen M, Schertz JC, Arriagada P, Keitel J, Müller H. The redesigned follitropin a pen injector for infertility treatment. Expert Opin. Drug Deliv. 8(6), 833–839 (2011).
  • Schertz JC, Saunders H, Hecker C, Lang B, Arriagada P. The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing. Expert Opin. Drug Deliv. 8(9), 1111–1120 (2011).
  • van der Gaast MH, Eijkemans MJ, van der Net JB et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod. Biomed. Online 13(4), 476–480 (2006).
  • Verberg MF, Eijkemans MJ, Macklon NS et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum. Reprod. Update 15(1), 5–12 (2009).
  • Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE Working Group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 26(7), 1616–1624 (2011).
  • Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum. Reprod. 15(10), 2145–2147 (2000).
  • Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum. Reprod. 16(5), 868–870 (2001).
  • Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols? Hum. Reprod. 14(12), 2959–2962 (1999).
  • D'Amato G, Caroppo E, Pasquadibisceglie A, Carone D, Vitti A, Vizziello GM. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertil. Steril. 81(6), 1572–1577 (2004).
  • Frankfurter D, Dayal M, Dubey A, Peak D, Gindoff P. Novel follicular-phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder. Fertil. Steril. 88(5), 1442–1445 (2007).
  • Mohamed KA, Davies WA, Allsopp J, Lashen H. Agonist ‘flare-up’ versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil. Steril. 83(2), 331–335 (2005).
  • Nikolettos N, Al-Hasani S, Felberbaum R et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur. J. Obstet. Gynecol. Reprod. Biol. 97(2), 202–207 (2001).
  • Orvieto R, Kruchkovich J, Rabinson J, Zohav E, Anteby EY, Meltcer S. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil. Steril. 90(1), 228–230 (2008).
  • Posada MN, Vlahos NP, Jurema MW, Bracero NJ, Wallach EE, Garcia JE. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization. Fertil. Steril. 80(1), 103–110 (2003).
  • Cheung LP, Lam PM, Lok IH et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum. Reprod. 20(3), 616–621 (2005).
  • Lainas TG, Sfontouris IA, Papanikolaou EG et al. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Hum. Reprod. 23(6), 1355–1358 (2008).
  • Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum. Reprod. 26(10), 2742–2749 (2011).
  • Kobayashi M, Nakano R, Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the ‘two-cell, two-gonadotrophin’ hypothesis of steroidogenesis in the human ovary. J. Endocrinol. 126(3), 483–488 (1990).
  • Howles CM. Luteininzing hormone supplementation in ART. In: How To Improve Your ART Success Rates. Kovacs G (Ed.). Cambridge University Press, Cambridge, UK, 99–104 (2011).
  • Fanchin R, Righini C, Olivennes F, Taieb J, de Ziegler D, Frydman R. Computerized assessment of endometrial echogenicity: clues to the endometrial effects of premature progesterone elevation. Fertil. Steril. 71(1), 174–181 (1999).
  • Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum. Reprod. Update 13(4), 343–355 (2007).
  • Bosch E, Labarta E, Crespo J et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum. Reprod. 25(8), 2092–2100 (2010).
  • Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod. Biomed. Online 21(4), 446–449 (2010).
  • Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod. Biomed. Online 23(2), 187–195 (2011).
  • European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J. Clin. Endocrinol. Metab. 86(6), 2607–2618 (2001).
  • Bosch E. Recombinant human FSH and recombinant human LH in a 2:1 ratio combination: a new tool for ovulation induction. Exp. Rev. Obstet. Gynecol. 4(5), 491–498 (2009).
  • Kolibianakis EM, Kalogeropoulou L, Griesinger G et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum. Reprod. Update 13(5), 445–452 (2007).
  • Mochtar MH, Van der Veen F, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst. Rev. 2, CD005070 (2007).
  • Weissman A, Howles CM. Treatment strategies in assisted reproduction for the low responder patient. In: Textbook of Assisted Reproductive Technologies – Laboratory and Clinical Perspectives (3rd Edition). Gardener DK, Weissman A, Howles CM, Shoham Z (Eds). Informa UK Ltd., Colchester, UK, 577–615 (2008).
  • Bosch E, Labarta E, Simón C, Remohi J, Pellicer A. The impact of luteinizing hormone supplementation in gonadotropin releasing hormone antagonist cycles. An age adjusted randomized trial. Fertil. Steril. 90, S41 (2008).
  • Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod. Biomed. Online 8(6), 635–643 (2004).
  • Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod. Biomed. Online 8(2), 175–182 (2004).
  • Matorras R, Prieto B, Exposito A et al. Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study. Reprod. Biomed. Online 19(6), 879–887 (2009).
  • Fábregues F, Creus M, Peñarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil. Steril. 85(4), 925–931 (2006).
  • Lisi F, Rinaldi L, Fishel S et al. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod. Biomed. Online 3(3), 190–194 (2001).
  • De Placido G, Alviggi C, Mollo A et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin. Endocrinol. 60(5), 637–643 (2004).
  • Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil. Steril. 82(6), 1521–1526 (2004).
  • Blumenfeld Z, Amit T. The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction. J. Pediatr. Endocrinol. Metab. 9(2), 145–162 (1996).
  • Yoshimura Y, Ando M, Nagamatsu S et al. Effects of insulin-like growth factor-I on follicle growth, oocyte maturation, and ovarian steroidogenesis and plasminogen activator activity in the rabbit. Biol. Reprod. 55(1), 152–160 (1996).
  • Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev. 1, CD000099 (2010).
  • Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 21(11), 2845–2849 (2006).
  • Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 25(10), 2496–2500 (2010).
  • Swain JE, Smith GD. Advances in embryo culture platforms: novel approaches to improve preimplantation embryo development through modifications of the microenvironment. Hum. Reprod. Update 17(4), 541–557 (2011).
  • Ebner T, Balaban B, Moser M et al. Automatic user-independent zona pellucida imaging at the oocyte stage allows for the prediction of preimplantation development. Fertil. Steril. 94(3), 913–920 (2010).
  • Madaschi C, Aoki T, de Almeida Ferreira Braga DP et al. Zona pellucida birefringence score and meiotic spindle visualization in relation to embryo development and ICSI outcomes. Reprod. Biomed. Online 18(5), 681–686 (2009).
  • Howles CM. Recombinant gonadotrophins in reproductive medicine: the gold standard of today. Reprod. Biomed. Online 12(1), 11–13 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.